Lilly combo cuts diabetic patients’ weight by up to 23% in 48 weeks
Eli Lilly’s experimental eloralintide-Mounjaro combination produced average weight loss of up to 23% in people with diabetes over 48 weeks. The result gives Lilly another late-stage obesity-treatment asset as it competes with Novo Nordisk in a rapidly expanding market.
STOCK PHOTO · MAURÍCIO MASCAROThe story
Participants receiving the highest dose lost an average of 54 pounds over 48 weeks, according to Bloomberg. Their A1C declined 2.9 percentage points from a baseline of 8.1%, and as many as three-quarters reached normal blood-sugar levels.
The combination pairs eloralintide, Lilly’s experimental obesity drug, with Mounjaro, its tirzepatide treatment for diabetes and obesity. The reported result adds to Lilly’s existing position in metabolic medicines and changes the competitive comparison with Novo Nordisk from single-drug performance toward combination regimens.
For Lilly, the commercial mechanism would run through demand for Mounjaro alongside a potential new eloralintide franchise. The reported weight-loss and glucose-control figures are from people with diabetes, so the read-through depends on how the combination performs across broader patient groups and in later-stage testing.
The report describes experimental results rather than an approved combination. Questions remain around durability, safety, dosing, regulatory requirements and whether the reported efficacy translates into a commercially viable treatment. The next evidence should come from additional clinical data and Lilly’s regulatory or development updates on eloralintide.
Our read · Thu, Oct 1
LLY’s eloralintide-Mounjaro combination delivered up to 23% average weight loss and a 2.9-point A1C decline in diabetics.
Why. The result expands Lilly’s potential obesity franchise beyond Mounjaro, with the reported 23% weight loss and 2.9-point A1C reduction providing a concrete efficacy hook. Lilly already generated $65.2B of FY2025 revenue and a 31.7% net margin, so a successful combination could build on an established commercial platform, but the treatment remains experimental and the next clinical and regulatory steps are not dated here.
Both cases
What could change this view: The read fails if later trials show weaker efficacy, unacceptable safety or dosing constraints, or regulators do not support the combination’s use.
Who reported it · 1
Keep reading
More on LLY
US judge lets Eli Lilly keep weight-loss ads in Novo Nordisk caseNovo Nordisk shares slide 7.7% as turnaround plans face analyst doubtLatest on the Wire
BlackRock bitcoin ETF posts $541.1 million outflow as tech sell-off spreadsPoland says Russian missiles and drone crashed during Ukraine assaultAnthropic debut fails to halt technology-led slide in US stocksUS MATCH Act puts ASML at center of China chip export disputeBeijing plans to bar young red-chip firms from overseas listingsContinue on the Wire →Latest on the Wire
German producer prices jump 8.1% in October as industrial inflation acceleratesChina seeks protections to restart US private-equity investmentsAMD shares fall 11% after Hunterbrook warns over China linksAnthropic IPO could become the largest in US history on ThursdayContinue on the Wire →Top this week
Nvidia allies lobby board to bring back Jensen Huang as CEONvidia chair rules out Huang return as CEO after 75% sales outlookAnthropic Said to Guide IPO Pricing Above Market RangeNvidia interim CEO Colette Kress faces first earnings test after HuangBitcoin nears $64,000 as Anthropic IPO lifts Nasdaq futures nearly 2%About this report
Reported by ZeroHedge as Lilly's "Incredible Hulk" Obesity Combo Delivers Record 23% Weight Loss In Diabetics
, . Who answers for this
The only report in this record. Closes are licensed end-of-day data from Databento; the move after a story is its first close against the close before it. How this is decided →
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →